Bristol Myers Squibb at Cell 2026
Nov 12–13, 2026 London, UK ~800 attendees Website
Bristol Myers Squibb takes part in 7 sessions at Cell 2026 in London. Its program centres on analytical and quality control strategy for cell and gene therapies, from phase-appropriate testing to commercial readiness. Other sessions cover scaling autologous CAR-T treatments, designing an end-to-end supply chain and where large drugmakers stand in the field.
| Organization | Cell 2026 Attendance |
|---|---|
Bristol Myers Squibb Princeton, New Jersey | |
Global drugmaker with marketed CAR-T cell therapies alongside medicines for cancer, immunology and cardiovascular disease. | Talk Thu Nov 12 9:25am–9:50am Advanced Technologies Driving The Next Wave Of Gene Therapy Cell and gene therapy Talk Thu Nov 12 10:15am–10:40am Phase Appropriate Analytical Strategies Including Comparability Analytics and characterizationManufacturing and CMC Panel Thu Nov 12 2:40pm–3:05pm Quality Control Strategies In Advanced CGTs Cell and gene therapyAnalytics and characterization Panel Thu Nov 12 2:40pm–3:05pm Where Does Big Pharma Stand In CGTs – And What Comes Next? Cell and gene therapy Talk Thu Nov 12 4:55pm–5:20pm From Vision And Concepts To Practical Execution - An Analytical Strategy And Lifecycle Execution Roadmap To Support Commercial Readiness And Operational Execution Success Analytics and characterizationManufacturing and CMC Talk Thu Nov 12 5:20pm–5:45pm One Lot, One Life: Scaling Hope for Patients with Autologous CART Treatments Cell and gene therapyManufacturing and CMC Talk Fri Nov 13 1:55pm–2:20pm Designing An End-To-End Supply Chain For CGTs Cell and gene therapyManufacturing and CMC |
Instantly find 20 buyers from Bristol Myers Squibb
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Cell 2026 or its organizers. Submit a correction